nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—CYP2D6—Hydroxyurea—head and neck cancer	0.14	0.218	CbGbCtD
Fluoxetine—ALB—Fluorouracil—head and neck cancer	0.109	0.169	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—head and neck cancer	0.0667	0.104	CbGbCtD
Fluoxetine—CYP1A2—Fluorouracil—head and neck cancer	0.065	0.101	CbGbCtD
Fluoxetine—CYP2C9—Fluorouracil—head and neck cancer	0.0586	0.0912	CbGbCtD
Fluoxetine—ABCB1—Vinblastine—head and neck cancer	0.0527	0.082	CbGbCtD
Fluoxetine—CYP2D6—Vinblastine—head and neck cancer	0.0496	0.0772	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—head and neck cancer	0.0434	0.0676	CbGbCtD
Fluoxetine—CYP3A4—Vinblastine—head and neck cancer	0.0315	0.0491	CbGbCtD
Fluoxetine—CYP3A4—Docetaxel—head and neck cancer	0.026	0.0405	CbGbCtD
Fluoxetine—Drowsiness—Hydroxyurea—head and neck cancer	0.00106	0.00336	CcSEcCtD
Fluoxetine—Amnesia—Fluorouracil—head and neck cancer	0.00106	0.00334	CcSEcCtD
Fluoxetine—Haemoglobin—Vinblastine—head and neck cancer	0.00105	0.00332	CcSEcCtD
Fluoxetine—Haemorrhage—Vinblastine—head and neck cancer	0.00105	0.00331	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00104	0.00329	CcSEcCtD
Fluoxetine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00104	0.00329	CcSEcCtD
Fluoxetine—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00104	0.00328	CcSEcCtD
Fluoxetine—Pharyngitis—Vinblastine—head and neck cancer	0.00104	0.00328	CcSEcCtD
Fluoxetine—Stomatitis—Hydroxyurea—head and neck cancer	0.00104	0.00327	CcSEcCtD
Fluoxetine—Bone pain—Docetaxel—head and neck cancer	0.00103	0.00326	CcSEcCtD
Fluoxetine—Lethargy—Fluorouracil—head and neck cancer	0.00101	0.0032	CcSEcCtD
Fluoxetine—Respiratory failure—Docetaxel—head and neck cancer	0.00101	0.00318	CcSEcCtD
Fluoxetine—Osteoarthritis—Fluorouracil—head and neck cancer	0.000995	0.00314	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000995	0.00314	CcSEcCtD
Fluoxetine—Hepatocellular injury—Docetaxel—head and neck cancer	0.000989	0.00312	CcSEcCtD
Fluoxetine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000989	0.00312	CcSEcCtD
Fluoxetine—Pulmonary embolism—Docetaxel—head and neck cancer	0.000989	0.00312	CcSEcCtD
Fluoxetine—Blood pressure increased—Docetaxel—head and neck cancer	0.000989	0.00312	CcSEcCtD
Fluoxetine—Haemoglobin—Hydroxyurea—head and neck cancer	0.000961	0.00303	CcSEcCtD
Fluoxetine—Haemorrhage—Hydroxyurea—head and neck cancer	0.000956	0.00301	CcSEcCtD
Fluoxetine—Hallucination—Hydroxyurea—head and neck cancer	0.000951	0.003	CcSEcCtD
Fluoxetine—Colitis—Docetaxel—head and neck cancer	0.000949	0.00299	CcSEcCtD
Fluoxetine—Irritability—Fluorouracil—head and neck cancer	0.000949	0.00299	CcSEcCtD
Fluoxetine—Cardiac arrest—Fluorouracil—head and neck cancer	0.000946	0.00298	CcSEcCtD
Fluoxetine—Candida infection—Docetaxel—head and neck cancer	0.000944	0.00298	CcSEcCtD
Fluoxetine—Fluid retention—Docetaxel—head and neck cancer	0.000939	0.00296	CcSEcCtD
Fluoxetine—Ataxia—Fluorouracil—head and neck cancer	0.000935	0.00295	CcSEcCtD
Fluoxetine—Neuropathy—Docetaxel—head and neck cancer	0.000928	0.00293	CcSEcCtD
Fluoxetine—Alopecia—Vinblastine—head and neck cancer	0.000926	0.00292	CcSEcCtD
Fluoxetine—Dry skin—Fluorouracil—head and neck cancer	0.000912	0.00287	CcSEcCtD
Fluoxetine—Oesophagitis—Docetaxel—head and neck cancer	0.000904	0.00285	CcSEcCtD
Fluoxetine—Neoplasm—Docetaxel—head and neck cancer	0.000894	0.00282	CcSEcCtD
Fluoxetine—Lightheadedness—Docetaxel—head and neck cancer	0.000885	0.00279	CcSEcCtD
Fluoxetine—Pulmonary oedema—Docetaxel—head and neck cancer	0.00088	0.00278	CcSEcCtD
Fluoxetine—Muscular weakness—Fluorouracil—head and neck cancer	0.000877	0.00277	CcSEcCtD
Fluoxetine—Dysphagia—Fluorouracil—head and neck cancer	0.00086	0.00271	CcSEcCtD
Fluoxetine—Chills—Hydroxyurea—head and neck cancer	0.000858	0.0027	CcSEcCtD
Fluoxetine—Eosinophilia—Fluorouracil—head and neck cancer	0.000851	0.00268	CcSEcCtD
Fluoxetine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000847	0.00267	CcSEcCtD
Fluoxetine—Alopecia—Hydroxyurea—head and neck cancer	0.000845	0.00266	CcSEcCtD
Fluoxetine—Anaemia—Vinblastine—head and neck cancer	0.000843	0.00266	CcSEcCtD
Fluoxetine—Angina pectoris—Fluorouracil—head and neck cancer	0.000837	0.00264	CcSEcCtD
Fluoxetine—Phlebitis—Docetaxel—head and neck cancer	0.000833	0.00263	CcSEcCtD
Fluoxetine—Thrombophlebitis—Docetaxel—head and neck cancer	0.000829	0.00261	CcSEcCtD
Fluoxetine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000825	0.0026	CcSEcCtD
Fluoxetine—Malaise—Vinblastine—head and neck cancer	0.000823	0.00259	CcSEcCtD
Fluoxetine—Vertigo—Vinblastine—head and neck cancer	0.00082	0.00259	CcSEcCtD
Fluoxetine—Leukopenia—Vinblastine—head and neck cancer	0.000817	0.00258	CcSEcCtD
Fluoxetine—Pancytopenia—Fluorouracil—head and neck cancer	0.000816	0.00257	CcSEcCtD
Fluoxetine—Deafness—Docetaxel—head and neck cancer	0.000802	0.00253	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000799	0.00252	CcSEcCtD
Fluoxetine—Hepatic failure—Docetaxel—head and neck cancer	0.000799	0.00252	CcSEcCtD
Fluoxetine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000792	0.0025	CcSEcCtD
Fluoxetine—Convulsion—Vinblastine—head and neck cancer	0.000791	0.00249	CcSEcCtD
Fluoxetine—Hypertension—Vinblastine—head and neck cancer	0.000788	0.00248	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000785	0.00247	CcSEcCtD
Fluoxetine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000772	0.00243	CcSEcCtD
Fluoxetine—Pneumonia—Fluorouracil—head and neck cancer	0.000771	0.00243	CcSEcCtD
Fluoxetine—Anaemia—Hydroxyurea—head and neck cancer	0.000769	0.00243	CcSEcCtD
Fluoxetine—Discomfort—Vinblastine—head and neck cancer	0.000767	0.00242	CcSEcCtD
Fluoxetine—Hot flush—Docetaxel—head and neck cancer	0.000767	0.00242	CcSEcCtD
Fluoxetine—Menopausal symptoms—Docetaxel—head and neck cancer	0.000761	0.0024	CcSEcCtD
Fluoxetine—Atrial fibrillation—Docetaxel—head and neck cancer	0.000757	0.00239	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000756	0.00238	CcSEcCtD
Fluoxetine—Renal impairment—Docetaxel—head and neck cancer	0.000754	0.00238	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000751	0.00237	CcSEcCtD
Fluoxetine—Myocardial infarction—Fluorouracil—head and neck cancer	0.000751	0.00237	CcSEcCtD
Fluoxetine—Dermatitis bullous—Docetaxel—head and neck cancer	0.000751	0.00237	CcSEcCtD
Fluoxetine—Malaise—Hydroxyurea—head and neck cancer	0.00075	0.00237	CcSEcCtD
Fluoxetine—Stomatitis—Fluorouracil—head and neck cancer	0.000747	0.00236	CcSEcCtD
Fluoxetine—Conjunctivitis—Fluorouracil—head and neck cancer	0.000745	0.00235	CcSEcCtD
Fluoxetine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000745	0.00235	CcSEcCtD
Fluoxetine—Leukopenia—Hydroxyurea—head and neck cancer	0.000745	0.00235	CcSEcCtD
Fluoxetine—Lethargy—Docetaxel—head and neck cancer	0.000733	0.00231	CcSEcCtD
Fluoxetine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000729	0.0023	CcSEcCtD
Fluoxetine—Epistaxis—Fluorouracil—head and neck cancer	0.000723	0.00228	CcSEcCtD
Fluoxetine—Convulsion—Hydroxyurea—head and neck cancer	0.000721	0.00227	CcSEcCtD
Fluoxetine—Hyponatraemia—Docetaxel—head and neck cancer	0.000721	0.00227	CcSEcCtD
Fluoxetine—Sinusitis—Fluorouracil—head and neck cancer	0.000719	0.00227	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000718	0.00226	CcSEcCtD
Fluoxetine—Anorexia—Vinblastine—head and neck cancer	0.00071	0.00224	CcSEcCtD
Fluoxetine—Migraine—Docetaxel—head and neck cancer	0.000707	0.00223	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000704	0.00222	CcSEcCtD
Fluoxetine—Discomfort—Hydroxyurea—head and neck cancer	0.0007	0.00221	CcSEcCtD
Fluoxetine—Haemoglobin—Fluorouracil—head and neck cancer	0.000692	0.00218	CcSEcCtD
Fluoxetine—Rhinitis—Fluorouracil—head and neck cancer	0.00069	0.00218	CcSEcCtD
Fluoxetine—Haemorrhage—Fluorouracil—head and neck cancer	0.000688	0.00217	CcSEcCtD
Fluoxetine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000685	0.00216	CcSEcCtD
Fluoxetine—Pharyngitis—Fluorouracil—head and neck cancer	0.000683	0.00215	CcSEcCtD
Fluoxetine—Ataxia—Docetaxel—head and neck cancer	0.000675	0.00213	CcSEcCtD
Fluoxetine—Infection—Hydroxyurea—head and neck cancer	0.000675	0.00213	CcSEcCtD
Fluoxetine—Paraesthesia—Vinblastine—head and neck cancer	0.000669	0.00211	CcSEcCtD
Fluoxetine—Dehydration—Docetaxel—head and neck cancer	0.000668	0.00211	CcSEcCtD
Fluoxetine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000665	0.0021	CcSEcCtD
Fluoxetine—Liver function test abnormal—Docetaxel—head and neck cancer	0.000663	0.00209	CcSEcCtD
Fluoxetine—Skin disorder—Hydroxyurea—head and neck cancer	0.00066	0.00208	CcSEcCtD
Fluoxetine—Dry skin—Docetaxel—head and neck cancer	0.000658	0.00207	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000656	0.00207	CcSEcCtD
Fluoxetine—Breast disorder—Docetaxel—head and neck cancer	0.000649	0.00205	CcSEcCtD
Fluoxetine—Anorexia—Hydroxyurea—head and neck cancer	0.000647	0.00204	CcSEcCtD
Fluoxetine—Decreased appetite—Vinblastine—head and neck cancer	0.000647	0.00204	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000646	0.00204	CcSEcCtD
Fluoxetine—Pain—Vinblastine—head and neck cancer	0.000637	0.00201	CcSEcCtD
Fluoxetine—Constipation—Vinblastine—head and neck cancer	0.000637	0.00201	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000633	0.002	CcSEcCtD
Fluoxetine—Dysphagia—Docetaxel—head and neck cancer	0.00062	0.00196	CcSEcCtD
Fluoxetine—Arrhythmia—Fluorouracil—head and neck cancer	0.000615	0.00194	CcSEcCtD
Fluoxetine—Feeling abnormal—Vinblastine—head and neck cancer	0.000614	0.00194	CcSEcCtD
Fluoxetine—Bronchospasm—Docetaxel—head and neck cancer	0.00061	0.00192	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000609	0.00192	CcSEcCtD
Fluoxetine—Alopecia—Fluorouracil—head and neck cancer	0.000608	0.00192	CcSEcCtD
Fluoxetine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000605	0.00191	CcSEcCtD
Fluoxetine—Angina pectoris—Docetaxel—head and neck cancer	0.000604	0.00191	CcSEcCtD
Fluoxetine—Somnolence—Hydroxyurea—head and neck cancer	0.000604	0.0019	CcSEcCtD
Fluoxetine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000598	0.00189	CcSEcCtD
Fluoxetine—Decreased appetite—Hydroxyurea—head and neck cancer	0.00059	0.00186	CcSEcCtD
Fluoxetine—Pancytopenia—Docetaxel—head and neck cancer	0.000589	0.00186	CcSEcCtD
Fluoxetine—Abdominal pain—Vinblastine—head and neck cancer	0.000589	0.00186	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000586	0.00185	CcSEcCtD
Fluoxetine—Fatigue—Hydroxyurea—head and neck cancer	0.000585	0.00185	CcSEcCtD
Fluoxetine—Pain—Hydroxyurea—head and neck cancer	0.000581	0.00183	CcSEcCtD
Fluoxetine—Constipation—Hydroxyurea—head and neck cancer	0.000581	0.00183	CcSEcCtD
Fluoxetine—Weight increased—Docetaxel—head and neck cancer	0.000565	0.00178	CcSEcCtD
Fluoxetine—Weight decreased—Docetaxel—head and neck cancer	0.000561	0.00177	CcSEcCtD
Fluoxetine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00056	0.00176	CcSEcCtD
Fluoxetine—Pneumonia—Docetaxel—head and neck cancer	0.000556	0.00175	CcSEcCtD
Fluoxetine—Anaemia—Fluorouracil—head and neck cancer	0.000554	0.00175	CcSEcCtD
Fluoxetine—Hypersensitivity—Vinblastine—head and neck cancer	0.000549	0.00173	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000548	0.00173	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000545	0.00172	CcSEcCtD
Fluoxetine—Renal failure—Docetaxel—head and neck cancer	0.000544	0.00171	CcSEcCtD
Fluoxetine—Myocardial infarction—Docetaxel—head and neck cancer	0.000542	0.00171	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000542	0.00171	CcSEcCtD
Fluoxetine—Stomatitis—Docetaxel—head and neck cancer	0.000539	0.0017	CcSEcCtD
Fluoxetine—Jaundice—Docetaxel—head and neck cancer	0.000539	0.0017	CcSEcCtD
Fluoxetine—Conjunctivitis—Docetaxel—head and neck cancer	0.000538	0.0017	CcSEcCtD
Fluoxetine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000537	0.00169	CcSEcCtD
Fluoxetine—Leukopenia—Fluorouracil—head and neck cancer	0.000536	0.00169	CcSEcCtD
Fluoxetine—Asthenia—Vinblastine—head and neck cancer	0.000534	0.00168	CcSEcCtD
Fluoxetine—Epistaxis—Docetaxel—head and neck cancer	0.000522	0.00165	CcSEcCtD
Fluoxetine—Convulsion—Fluorouracil—head and neck cancer	0.000519	0.00164	CcSEcCtD
Fluoxetine—Chest pain—Fluorouracil—head and neck cancer	0.00051	0.00161	CcSEcCtD
Fluoxetine—Myalgia—Fluorouracil—head and neck cancer	0.00051	0.00161	CcSEcCtD
Fluoxetine—Diarrhoea—Vinblastine—head and neck cancer	0.00051	0.00161	CcSEcCtD
Fluoxetine—Discomfort—Fluorouracil—head and neck cancer	0.000504	0.00159	CcSEcCtD
Fluoxetine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.0005	0.00158	CcSEcCtD
Fluoxetine—Haemoglobin—Docetaxel—head and neck cancer	0.000499	0.00157	CcSEcCtD
Fluoxetine—Rhinitis—Docetaxel—head and neck cancer	0.000498	0.00157	CcSEcCtD
Fluoxetine—Haemorrhage—Docetaxel—head and neck cancer	0.000497	0.00157	CcSEcCtD
Fluoxetine—Hepatitis—Docetaxel—head and neck cancer	0.000497	0.00157	CcSEcCtD
Fluoxetine—Hypoaesthesia—Docetaxel—head and neck cancer	0.000494	0.00156	CcSEcCtD
Fluoxetine—Confusional state—Fluorouracil—head and neck cancer	0.000493	0.00155	CcSEcCtD
Fluoxetine—Pharyngitis—Docetaxel—head and neck cancer	0.000493	0.00155	CcSEcCtD
Fluoxetine—Dizziness—Vinblastine—head and neck cancer	0.000492	0.00155	CcSEcCtD
Fluoxetine—Oedema peripheral—Docetaxel—head and neck cancer	0.000489	0.00154	CcSEcCtD
Fluoxetine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000489	0.00154	CcSEcCtD
Fluoxetine—Asthenia—Hydroxyurea—head and neck cancer	0.000487	0.00154	CcSEcCtD
Fluoxetine—Infection—Fluorouracil—head and neck cancer	0.000486	0.00153	CcSEcCtD
Fluoxetine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000479	0.00151	CcSEcCtD
Fluoxetine—Visual impairment—Docetaxel—head and neck cancer	0.000479	0.00151	CcSEcCtD
Fluoxetine—Tachycardia—Fluorouracil—head and neck cancer	0.000477	0.0015	CcSEcCtD
Fluoxetine—Vomiting—Vinblastine—head and neck cancer	0.000473	0.00149	CcSEcCtD
Fluoxetine—Erythema multiforme—Docetaxel—head and neck cancer	0.00047	0.00148	CcSEcCtD
Fluoxetine—Headache—Vinblastine—head and neck cancer	0.000467	0.00147	CcSEcCtD
Fluoxetine—Anorexia—Fluorouracil—head and neck cancer	0.000466	0.00147	CcSEcCtD
Fluoxetine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000465	0.00147	CcSEcCtD
Fluoxetine—Hypotension—Fluorouracil—head and neck cancer	0.000457	0.00144	CcSEcCtD
Fluoxetine—Dizziness—Hydroxyurea—head and neck cancer	0.000449	0.00142	CcSEcCtD
Fluoxetine—Chills—Docetaxel—head and neck cancer	0.000446	0.00141	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000445	0.0014	CcSEcCtD
Fluoxetine—Arrhythmia—Docetaxel—head and neck cancer	0.000444	0.0014	CcSEcCtD
Fluoxetine—Nausea—Vinblastine—head and neck cancer	0.000442	0.00139	CcSEcCtD
Fluoxetine—Insomnia—Fluorouracil—head and neck cancer	0.000442	0.00139	CcSEcCtD
Fluoxetine—Paraesthesia—Fluorouracil—head and neck cancer	0.000439	0.00138	CcSEcCtD
Fluoxetine—Alopecia—Docetaxel—head and neck cancer	0.000439	0.00138	CcSEcCtD
Fluoxetine—Dyspnoea—Fluorouracil—head and neck cancer	0.000436	0.00137	CcSEcCtD
Fluoxetine—Mental disorder—Docetaxel—head and neck cancer	0.000435	0.00137	CcSEcCtD
Fluoxetine—Somnolence—Fluorouracil—head and neck cancer	0.000435	0.00137	CcSEcCtD
Fluoxetine—Malnutrition—Docetaxel—head and neck cancer	0.000432	0.00136	CcSEcCtD
Fluoxetine—Vomiting—Hydroxyurea—head and neck cancer	0.000432	0.00136	CcSEcCtD
Fluoxetine—Dyspepsia—Fluorouracil—head and neck cancer	0.00043	0.00136	CcSEcCtD
Fluoxetine—Rash—Hydroxyurea—head and neck cancer	0.000428	0.00135	CcSEcCtD
Fluoxetine—Dermatitis—Hydroxyurea—head and neck cancer	0.000428	0.00135	CcSEcCtD
Fluoxetine—Headache—Hydroxyurea—head and neck cancer	0.000425	0.00134	CcSEcCtD
Fluoxetine—Decreased appetite—Fluorouracil—head and neck cancer	0.000425	0.00134	CcSEcCtD
Fluoxetine—Dysgeusia—Docetaxel—head and neck cancer	0.000423	0.00133	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000422	0.00133	CcSEcCtD
Fluoxetine—Back pain—Docetaxel—head and neck cancer	0.000418	0.00132	CcSEcCtD
Fluoxetine—Pain—Fluorouracil—head and neck cancer	0.000418	0.00132	CcSEcCtD
Fluoxetine—Muscle spasms—Docetaxel—head and neck cancer	0.000416	0.00131	CcSEcCtD
Fluoxetine—Nausea—Hydroxyurea—head and neck cancer	0.000403	0.00127	CcSEcCtD
Fluoxetine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000403	0.00127	CcSEcCtD
Fluoxetine—Anaemia—Docetaxel—head and neck cancer	0.0004	0.00126	CcSEcCtD
Fluoxetine—Urticaria—Fluorouracil—head and neck cancer	0.000388	0.00122	CcSEcCtD
Fluoxetine—Syncope—Docetaxel—head and neck cancer	0.000388	0.00122	CcSEcCtD
Fluoxetine—Leukopenia—Docetaxel—head and neck cancer	0.000387	0.00122	CcSEcCtD
Fluoxetine—Body temperature increased—Fluorouracil—head and neck cancer	0.000386	0.00122	CcSEcCtD
Fluoxetine—Palpitations—Docetaxel—head and neck cancer	0.000382	0.0012	CcSEcCtD
Fluoxetine—Loss of consciousness—Docetaxel—head and neck cancer	0.00038	0.0012	CcSEcCtD
Fluoxetine—Cough—Docetaxel—head and neck cancer	0.000377	0.00119	CcSEcCtD
Fluoxetine—Convulsion—Docetaxel—head and neck cancer	0.000375	0.00118	CcSEcCtD
Fluoxetine—Hypertension—Docetaxel—head and neck cancer	0.000373	0.00118	CcSEcCtD
Fluoxetine—Myalgia—Docetaxel—head and neck cancer	0.000368	0.00116	CcSEcCtD
Fluoxetine—Chest pain—Docetaxel—head and neck cancer	0.000368	0.00116	CcSEcCtD
Fluoxetine—Arthralgia—Docetaxel—head and neck cancer	0.000368	0.00116	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000366	0.00115	CcSEcCtD
Fluoxetine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00036	0.00114	CcSEcCtD
Fluoxetine—Dry mouth—Docetaxel—head and neck cancer	0.00036	0.00114	CcSEcCtD
Fluoxetine—Confusional state—Docetaxel—head and neck cancer	0.000356	0.00112	CcSEcCtD
Fluoxetine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000353	0.00111	CcSEcCtD
Fluoxetine—Infection—Docetaxel—head and neck cancer	0.000351	0.00111	CcSEcCtD
Fluoxetine—Shock—Docetaxel—head and neck cancer	0.000347	0.00109	CcSEcCtD
Fluoxetine—Pruritus—Fluorouracil—head and neck cancer	0.000346	0.00109	CcSEcCtD
Fluoxetine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000345	0.00109	CcSEcCtD
Fluoxetine—Tachycardia—Docetaxel—head and neck cancer	0.000344	0.00109	CcSEcCtD
Fluoxetine—Skin disorder—Docetaxel—head and neck cancer	0.000343	0.00108	CcSEcCtD
Fluoxetine—Anorexia—Docetaxel—head and neck cancer	0.000336	0.00106	CcSEcCtD
Fluoxetine—Diarrhoea—Fluorouracil—head and neck cancer	0.000334	0.00105	CcSEcCtD
Fluoxetine—Hypotension—Docetaxel—head and neck cancer	0.00033	0.00104	CcSEcCtD
Fluoxetine—Dizziness—Fluorouracil—head and neck cancer	0.000323	0.00102	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000321	0.00101	CcSEcCtD
Fluoxetine—Insomnia—Docetaxel—head and neck cancer	0.000319	0.00101	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—head and neck cancer	0.000317	0.000999	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—head and neck cancer	0.000315	0.000992	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—head and neck cancer	0.000314	0.000989	CcSEcCtD
Fluoxetine—Vomiting—Fluorouracil—head and neck cancer	0.000311	0.00098	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—head and neck cancer	0.000311	0.000979	CcSEcCtD
Fluoxetine—Rash—Fluorouracil—head and neck cancer	0.000308	0.000972	CcSEcCtD
Fluoxetine—Dermatitis—Fluorouracil—head and neck cancer	0.000308	0.000971	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—head and neck cancer	0.000307	0.000967	CcSEcCtD
Fluoxetine—Headache—Fluorouracil—head and neck cancer	0.000306	0.000966	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000305	0.000961	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—head and neck cancer	0.000304	0.000959	CcSEcCtD
Fluoxetine—Pain—Docetaxel—head and neck cancer	0.000302	0.000951	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—head and neck cancer	0.000302	0.000951	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—head and neck cancer	0.000291	0.000917	CcSEcCtD
Fluoxetine—Nausea—Fluorouracil—head and neck cancer	0.00029	0.000916	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000289	0.00091	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—head and neck cancer	0.000279	0.00088	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—head and neck cancer	0.000279	0.00088	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—head and neck cancer	0.00026	0.00082	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—head and neck cancer	0.000253	0.000798	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—head and neck cancer	0.00025	0.000787	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—head and neck cancer	0.000241	0.000761	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—head and neck cancer	0.000233	0.000736	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—head and neck cancer	0.000224	0.000707	CcSEcCtD
Fluoxetine—Rash—Docetaxel—head and neck cancer	0.000222	0.000701	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—head and neck cancer	0.000222	0.000701	CcSEcCtD
Fluoxetine—Headache—Docetaxel—head and neck cancer	0.000221	0.000697	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—head and neck cancer	0.00021	0.000661	CcSEcCtD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	6.33e-05	0.00156	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	6.32e-05	0.00156	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	6.27e-05	0.00155	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	6.24e-05	0.00154	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	6.24e-05	0.00154	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	6.24e-05	0.00154	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KISS1—head and neck cancer	6.23e-05	0.00154	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	6.08e-05	0.0015	CbGpPWpGaD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—head and neck cancer	6.06e-05	0.0015	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	6.03e-05	0.00149	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	6e-05	0.00148	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	5.94e-05	0.00147	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—GRP—head and neck cancer	5.91e-05	0.00146	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—UROD—head and neck cancer	5.81e-05	0.00144	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—UROD—head and neck cancer	5.67e-05	0.0014	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—GRP—head and neck cancer	5.65e-05	0.0014	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	5.63e-05	0.00139	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TP53—head and neck cancer	5.61e-05	0.00138	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	5.43e-05	0.00134	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	5.36e-05	0.00132	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—UROD—head and neck cancer	5.35e-05	0.00132	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—head and neck cancer	5.32e-05	0.00131	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—UROD—head and neck cancer	5.3e-05	0.00131	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	5.19e-05	0.00128	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	5.15e-05	0.00127	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—GRP—head and neck cancer	5.13e-05	0.00127	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	5.08e-05	0.00125	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.02e-05	0.00124	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	5.01e-05	0.00124	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—UROD—head and neck cancer	4.53e-05	0.00112	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.51e-05	0.00111	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	4.38e-05	0.00108	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	4.33e-05	0.00107	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KISS1—head and neck cancer	4.24e-05	0.00105	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	4.19e-05	0.00103	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	4.16e-05	0.00103	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	4.16e-05	0.00103	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	4.15e-05	0.00102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	4.13e-05	0.00102	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.11e-05	0.00102	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—PIK3CA—head and neck cancer	4.04e-05	0.000998	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	3.97e-05	0.000981	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	3.92e-05	0.000968	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	3.8e-05	0.000938	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	3.71e-05	0.000917	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KISS1—head and neck cancer	3.68e-05	0.000909	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	3.62e-05	0.000893	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	3.62e-05	0.000893	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	3.61e-05	0.000892	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	3.53e-05	0.000871	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.51e-05	0.000868	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—PIK3CA—head and neck cancer	3.51e-05	0.000866	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—UROD—head and neck cancer	3.5e-05	0.000863	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GRP—head and neck cancer	3.49e-05	0.000862	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT6—head and neck cancer	3.39e-05	0.000837	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	3.34e-05	0.000825	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	3.32e-05	0.00082	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NAT2—head and neck cancer	3.19e-05	0.000789	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	3.19e-05	0.000787	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	3.14e-05	0.000775	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NAT2—head and neck cancer	3.12e-05	0.000771	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	3.08e-05	0.000759	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GRP—head and neck cancer	3.03e-05	0.000749	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—YAP1—head and neck cancer	3e-05	0.000741	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT6—head and neck cancer	2.94e-05	0.000727	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	2.9e-05	0.000717	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.86e-05	0.000705	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.83e-05	0.000698	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	2.82e-05	0.000697	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—DPYD—head and neck cancer	2.8e-05	0.000692	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	2.78e-05	0.000686	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—DPYD—head and neck cancer	2.74e-05	0.000676	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NAT2—head and neck cancer	2.69e-05	0.000664	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	2.67e-05	0.000659	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—YAP1—head and neck cancer	2.66e-05	0.000656	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	2.63e-05	0.000649	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—YAP1—head and neck cancer	2.61e-05	0.000643	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—YAP1—head and neck cancer	2.6e-05	0.000641	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.56e-05	0.000633	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	2.54e-05	0.000627	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.54e-05	0.000627	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	2.5e-05	0.000617	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	2.5e-05	0.000617	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NAT2—head and neck cancer	2.41e-05	0.000596	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—DPYD—head and neck cancer	2.36e-05	0.000582	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NAT2—head and neck cancer	2.36e-05	0.000582	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.34e-05	0.000577	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.31e-05	0.000571	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—YAP1—head and neck cancer	2.24e-05	0.000552	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NAT2—head and neck cancer	2.22e-05	0.000548	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	2.2e-05	0.000544	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NAT2—head and neck cancer	2.2e-05	0.000543	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	2.17e-05	0.000536	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—DPYD—head and neck cancer	2.12e-05	0.000523	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	2.1e-05	0.000518	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—DPYD—head and neck cancer	2.07e-05	0.00051	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—YAP1—head and neck cancer	2.01e-05	0.000496	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2e-05	0.000493	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.98e-05	0.000488	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—YAP1—head and neck cancer	1.96e-05	0.000484	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—DPYD—head and neck cancer	1.95e-05	0.000481	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—DPYD—head and neck cancer	1.93e-05	0.000476	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NAT2—head and neck cancer	1.88e-05	0.000464	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—YAP1—head and neck cancer	1.85e-05	0.000456	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—YAP1—head and neck cancer	1.83e-05	0.000452	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.8e-05	0.000445	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	1.77e-05	0.000438	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2—head and neck cancer	1.73e-05	0.000428	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2—head and neck cancer	1.71e-05	0.000423	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.68e-05	0.000415	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—DPYD—head and neck cancer	1.65e-05	0.000407	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TYMS—head and neck cancer	1.6e-05	0.000394	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTM1—head and neck cancer	1.58e-05	0.000389	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—head and neck cancer	1.58e-05	0.000389	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—YAP1—head and neck cancer	1.57e-05	0.000386	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TYMS—head and neck cancer	1.56e-05	0.000385	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTM1—head and neck cancer	1.54e-05	0.000381	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GPX1—head and neck cancer	1.51e-05	0.000373	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.51e-05	0.000373	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—head and neck cancer	1.51e-05	0.000372	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1A1—head and neck cancer	1.5e-05	0.000369	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GPX1—head and neck cancer	1.48e-05	0.000365	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.47e-05	0.000362	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.46e-05	0.000361	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—head and neck cancer	1.45e-05	0.000359	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NAT2—head and neck cancer	1.45e-05	0.000358	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.38e-05	0.00034	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—head and neck cancer	1.38e-05	0.00034	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—head and neck cancer	1.37e-05	0.000338	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH1—head and neck cancer	1.35e-05	0.000334	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TYMS—head and neck cancer	1.34e-05	0.000332	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—head and neck cancer	1.33e-05	0.000328	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.32e-05	0.000325	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—head and neck cancer	1.31e-05	0.000323	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—DPYD—head and neck cancer	1.27e-05	0.000314	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GPX1—head and neck cancer	1.27e-05	0.000314	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	1.27e-05	0.000313	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1A1—head and neck cancer	1.26e-05	0.000311	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—YAP1—head and neck cancer	1.21e-05	0.000298	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TYMS—head and neck cancer	1.21e-05	0.000298	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	1.21e-05	0.000298	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	1.2e-05	0.000297	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.2e-05	0.000296	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—head and neck cancer	1.19e-05	0.000294	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TYMS—head and neck cancer	1.18e-05	0.000291	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.18e-05	0.00029	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—head and neck cancer	1.17e-05	0.00029	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—head and neck cancer	1.16e-05	0.000287	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	1.15e-05	0.000284	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GPX1—head and neck cancer	1.14e-05	0.000282	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—head and neck cancer	1.14e-05	0.00028	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.13e-05	0.000279	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GPX1—head and neck cancer	1.11e-05	0.000275	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—head and neck cancer	1.11e-05	0.000274	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.1e-05	0.000272	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—head and neck cancer	1.1e-05	0.000272	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—head and neck cancer	1.1e-05	0.000272	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—head and neck cancer	1.1e-05	0.000271	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.1e-05	0.000271	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.09e-05	0.000268	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—head and neck cancer	1.05e-05	0.000259	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GPX1—head and neck cancer	1.05e-05	0.000259	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	1.05e-05	0.000258	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	1.05e-05	0.000258	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	1.05e-05	0.000258	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GPX1—head and neck cancer	1.04e-05	0.000257	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.04e-05	0.000257	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.03e-05	0.000255	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.03e-05	0.000254	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.03e-05	0.000253	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1e-05	0.000247	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	9.68e-06	0.000239	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	9.41e-06	0.000232	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—head and neck cancer	9.4e-06	0.000232	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—head and neck cancer	9.31e-06	0.00023	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—head and neck cancer	9.29e-06	0.000229	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.29e-06	0.000229	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—head and neck cancer	9.28e-06	0.000229	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	9.08e-06	0.000224	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	9.07e-06	0.000224	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPX1—head and neck cancer	8.9e-06	0.00022	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—head and neck cancer	8.89e-06	0.00022	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	8.81e-06	0.000217	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	8.76e-06	0.000216	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—head and neck cancer	8.69e-06	0.000215	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	8.54e-06	0.000211	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	8.47e-06	0.000209	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	8.4e-06	0.000207	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	8.17e-06	0.000202	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—head and neck cancer	8.08e-06	0.0002	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	7.91e-06	0.000195	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	7.88e-06	0.000194	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	7.83e-06	0.000193	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—head and neck cancer	7.76e-06	0.000191	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	7.6e-06	0.000188	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—head and neck cancer	7.58e-06	0.000187	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—head and neck cancer	7.49e-06	0.000185	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	7.48e-06	0.000185	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	7.42e-06	0.000183	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—head and neck cancer	7.25e-06	0.000179	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.24e-06	0.000179	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—head and neck cancer	7.17e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	7.12e-06	0.000176	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	7.12e-06	0.000176	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	6.87e-06	0.00017	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPX1—head and neck cancer	6.87e-06	0.000169	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	6.8e-06	0.000168	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	6.8e-06	0.000168	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—head and neck cancer	6.72e-06	0.000166	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—head and neck cancer	6.56e-06	0.000162	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—head and neck cancer	6.53e-06	0.000161	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	6.5e-06	0.00016	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	6.18e-06	0.000153	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—head and neck cancer	6.18e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	6.18e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	6.18e-06	0.000153	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—head and neck cancer	6.13e-06	0.000151	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—head and neck cancer	5.98e-06	0.000148	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—head and neck cancer	5.86e-06	0.000145	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—head and neck cancer	5.72e-06	0.000141	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	5.72e-06	0.000141	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—head and neck cancer	5.47e-06	0.000135	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—head and neck cancer	5.39e-06	0.000133	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	5.36e-06	0.000132	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—head and neck cancer	5.35e-06	0.000132	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—head and neck cancer	5.34e-06	0.000132	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—head and neck cancer	5.24e-06	0.000129	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—head and neck cancer	5.19e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	5.05e-06	0.000125	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	4.96e-06	0.000123	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—head and neck cancer	4.61e-06	0.000114	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—head and neck cancer	4.57e-06	0.000113	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—head and neck cancer	4.47e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	4.38e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—head and neck cancer	4.37e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	4.14e-06	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—head and neck cancer	4.04e-06	9.98e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—head and neck cancer	4.04e-06	9.96e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.8e-06	9.39e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.77e-06	9.31e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—head and neck cancer	3.76e-06	9.29e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—head and neck cancer	3.52e-06	8.7e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—head and neck cancer	3.38e-06	8.34e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—head and neck cancer	3.3e-06	8.14e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	3.22e-06	7.95e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—head and neck cancer	3.11e-06	7.67e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—head and neck cancer	3.08e-06	7.6e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—head and neck cancer	2.63e-06	6.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.49e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—head and neck cancer	2.03e-06	5.01e-05	CbGpPWpGaD
